Stock CRNO B CERENO SCIENTIFIC AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up

News Cereno Scientific AB (publ) NORDIC GROWTH MARKET

Equities

CRNO B

SE0008241558

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2023-06-19 pm EDT 		5-day change 1st Jan Change
0.521 SEK -7.13% Intraday chart for Cereno Scientific AB (publ) +7.98% -76.90%
Jul. 10 Cereno Scientific Extends Financial Runway by Extending Loan Maturity Date CI
Jul. 09 Cereno Scientific Secures New Patents for Hypertension Drug Candidate MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cereno Scientific Extends Financial Runway by Extending Loan Maturity Date
AQ
Cereno Scientific Extends Financial Runway by Extending Loan Maturity Date
CI
Cereno Scientific reports acquired warrants within the framework of the incentive program resolved at the Annual General Meeting
AQ
Cereno Scientific Secures New Patents for Hypertension Drug Candidate
MT
Cereno Scientific expands patent protection for PAH drug candidate CS1:s second and third patent family
AQ
BioStock: Cereno's CEO comments on progress with CS1 and CS014
AQ
Cereno Scientific announces final milestone payment to Emeriti Bio for CS014
AQ
Cereno Scientific's Board of Directors and Executive Management enter into lock-up agreements
AQ
First subject dosed in Cereno Scientifics first-in-human Phase I trial of novel HDAC inhibitor CS014
AQ
First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014
CI
Cereno Scientific's Phase II trial with CS1 in Pulmonary Arterial Hypertension is closing for recruitment and proceeding to topline
AQ
Cereno Scientific AB Announces Phase Ii Trial with Cs1 in Pulmonary Arterial Hypertension Is Closing for Recruitment and Proceeding Topline
CI
Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I
AQ
BioStock: Cereno's CEO - "CS014 adds potential for cardiovascular disease patients"
AQ
Cereno Scientific Gets EU Approval for First-In-Human Trial for Antithrombotic Drug Candidate
MT
Cereno Scientific granted approval from, EMA to initiate first-in-human Phase I trial with novel epigenetic HDAC inhibitor, CS014
AQ
Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014
CI
Preclinical data for Cereno Scientific's drug candidate CS585 showing high selectivity for the IP receptor presented at the EHA 2024 Hybrid Congress
AQ
Cereno Scientific AB Presents Preclinical Data At EHA 2024 Hybrid Congress
CI
Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRNO B Stock
  4. CRNO B Stock
  5. News Cereno Scientific AB (publ)